Troy Rohn, Ph.D.

Consultant & Lead Scientific Advisor

Dr. Troy Rohn, Professor, Department of Biological Sciences, Boise State University, joined the company in October 2015 as lead scientific advisor. Dr. Rohn is assisting us in shaping and guiding our TauC3 antibody program.

Dr. Rohn graduated in 1990 from the University of California at Davis with a B.S. in Physiology. He received his Ph.D. in Pharmacology from the University of Washington, Seattle in 1994. His interests include the role of apoptosis in neurodegenerative diseases. Dr. Rohn conducted Postdoctoral studies at UC Irvine at the Institute of Brain Aging and Dementia under the direction of Dr. Carl Cotman. Dr. Rohn continues to collaborate extensively with UC Irvine and in addition with Dr. Eliezer Masliah at UC San Diego.

The primary focus of Dr. Rohn’s laboratory at Boise State University is the research of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Pick’s disease, frontal temporal dementia and vascular dementia. Dr. Rohn has conducted numerous experiments with affinity-purified tau caspase cleavage antibodies and has written extensively about the TauC3 antibody, developed by Lester Binder’s group at Northwestern University, which is under license to Intellect Neurosciences, Inc.